fbpx

Orexigen Therapeutics, Inc.

Robbins LLP Is Investigating the Directors and Officers of Orexigen Therapeutics, Inc.

Robbins LLP is investigating whether certain officers and directors of Orexigen Therapeutics, Inc. (NASDAQ: OREX) (“Orexigen”) breached their fiduciary duties to shareholders. Orexigen focuses on the development of pharmaceutical product candidates for the treatment of obesity.

Orexigen shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly. You can also contact attorney Darnell R. Donahue at (800) 350-6003.

Send us a message for more information.